Huntington’s Disease News and Research

RSS

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

In a development that could pave the way for treatment for rare neurological diseases and clues to more common ones, physician-scientists at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have secured a grant to establish a clinical site for the Network for Excellence in Neuroscience Clinical Trials.

2 Dec 2011

Dantrolene reduces severity of walking and balance problems linked with HD

Huntington's disease (HD) is characterized by ongoing destruction of specific neurons within the brain. It affects a person's ability to walk, talk, and think - leading to involuntary movement and loss of muscle co-ordination. New research published in BioMed Central's open access journal Molecular Neurodegeneration shows that the RyanR inhibitor Dantrolene is able to reduce the severity of walking and balance problems in a mouse model of HD.

24 Nov 2011

Carefully selected young, healthy neurons can repair brain circuitry

Neuron transplants have repaired brain circuitry and substantially normalized function in mice with a brain disorder, an advance indicating that key areas of the mammalian brain are more reparable than was widely believed.

24 Nov 2011

New protein in the fruit fly eye may shed light on neurodegenerative diseases

Researchers at the University of Wisconsin-Madison and collaborators have discovered a powerful new protein in the eye of the fruit fly that may shed light on blinding diseases and other sensory problems in humans.

18 Nov 2011

New stem cell technique hopes to replace damaged cells in Parkinson's

Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson's disease. The technique could be developed for application in other degenerative conditions.

13 Nov 2011

Damaged mitochondria equivalent to an environmental disaster in the cell

Current thinking about Parkinson's disease is that it's a disorder of mitochondria, the energy-producing organelles inside cells, causing neurons in the brain's substantia nigra to die or become impaired.

11 Nov 2011

New cellular targets for devastating neurological disorder

In a paper published in the November 9 issue of The Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine and University of Washington describe in deeper detail the pathology of a devastating neurological disorder, but also reveal new cellular targets for possibly slowing its development.

10 Nov 2011

Researchers discover key mechanism responsible for degrading ubiquitinated protein aggregates

Researchers at the RIKEN Brain Science Institute (BSI) have discovered a key mechanism responsible for selectively degrading aggregates of ubiquitinated proteins from the cell.

7 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

Scientists discover how toxic form of htt protein causes Huntington's symptoms

Scientists at the Gladstone Institutes have discovered how a form of the protein linked to Huntington's disease influences the timing and severity of its symptoms, offering new avenues for treating not only this disease, but also a variety of similar conditions.

31 Oct 2011

Johns Hopkins Brain Science Institute organizes Drug Discovery in Academia symposium

A symposium to be hosted by the Johns Hopkins Brain Science Institute (BSi) on Oct. 18 at the Baltimore Convention Center will bring together the pharmaceutical industry and academic-based research institutions with the common goal of exploring how the two can best work together to enhance and facilitate the discovery of new drugs.

15 Oct 2011

Normal Htt protein regulates formation of cellular structures in mouse model of HD

Huntington disease is a devastating neurogenerative disorder that causes a progressive loss of functional capacity and reduced life span. It is an inherited condition caused by a mutant HTT gene. Although this has been known for many years, the functions of the normal Htt protein and the mechanisms by which the mutant protein generated from the mutant HTT gene causes disease are not well understood.

11 Oct 2011

Viewpoints: Defining 'essential benefits;' 'Super committee' special pleadings; Limiting consumer choice in prescriptions

The IOM report acknowledges that "the determination of the (essential health benefits) is a politically and socially charged endeavor."

7 Oct 2011

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

The Cedars-Sinai Regenerative Medicine Institute has opened a new Induced Pluripotent Stem Cell (iPSC) Core Facility to produce powerful cells capable of making all tissues of the body from adult human skin cells.

23 Sep 2011

Clinical trial to evaluate TAU's stem cell technology for ALS

The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

21 Sep 2011

International patient groups anxiously await start of Huntington’s trial

Prana Biotechnology Limited received a very positive reaction from international patient groups and researchers at this week’s World Congress on Huntington’s Disease in Melbourne. The company had a major presence at the Congress and the Prana team has held numerous meetings and conversations with patient groups and researchers.

15 Sep 2011

Data on veterans affairs hospitals shows high rates of readmissions

The Veterans Health Administration, the largest integrated health care system in the country, has long employed many of the approaches Medicare is pushing on all hospitals to reduce unnecessary readmissions. But new data show VA hospital patients are just as likely to end up back in a hospital bed as are patients at private hospitals.

13 Sep 2011

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington’s patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington’s often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.

12 Sep 2011

University of Adelaide research focuses on techniques to treat swallowing disorders

A simple function that most of us take for granted - swallowing - is the focus of University of Adelaide research which could help thousands of stroke sufferers around the world.

12 Sep 2011

New treatment strategy for dominant forms of muscular dystrophy

Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.

12 Sep 2011

Huntington’s Disease News and Research

Einstein, Montefiore receive NINDS grant to establish clinical site for NeuroNEXT

Dantrolene reduces severity of walking and balance problems linked with HD

Carefully selected young, healthy neurons can repair brain circuitry

New protein in the fruit fly eye may shed light on neurodegenerative diseases

New stem cell technique hopes to replace damaged cells in Parkinson's

Damaged mitochondria equivalent to an environmental disaster in the cell

New cellular targets for devastating neurological disorder

Researchers discover key mechanism responsible for degrading ubiquitinated protein aggregates

Scientists identify mechanism by which GBM promotes neurodegeneration

Scientists discover how toxic form of htt protein causes Huntington's symptoms

Johns Hopkins Brain Science Institute organizes Drug Discovery in Academia symposium

Normal Htt protein regulates formation of cellular structures in mouse model of HD

Viewpoints: Defining 'essential benefits;' 'Super committee' special pleadings; Limiting consumer choice in prescriptions

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

Clinical trial to evaluate TAU's stem cell technology for ALS

International patient groups anxiously await start of Huntington’s trial

Data on veterans affairs hospitals shows high rates of readmissions

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

University of Adelaide research focuses on techniques to treat swallowing disorders

New treatment strategy for dominant forms of muscular dystrophy

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News